Paper Details

  1. Home
  2. Paper Details

The effects of combined raloxifene and oral estrogen on vasomotor symptoms and endometrial safety.

Author: GassMargery L S, MuramDavid, PlouffeLeo, QuYongming, StovallDale W, UtianWulf H, WongMayme

Controlled Clinical TrialA clinical trial that evaluates the effectiveness of a treatment by comparing a group that receives the intervention with a group that receives a placebo or standard treatment.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This randomized, double-blind clinical trial compared the effects of 52 weeks' treatment with either raloxifene 60 mg/day alone (RLX) or in combination with 17beta-estradiol 1 mg/day (RLX + E) on vasomotor symptoms and endometrial safety in postmenopausal women who transitioned from estrogen-progestin therapy. The study found that vasomotor symptoms were unchanged from baseline with RLX treatment, but these symptoms were significantly reduced with combined RLX + E therapy. Signs of endometrial stimulation were observed in the RLX + E group.
Paper Details　
Original Abstract of the Article :
OBJECTIVE: To compare effects of 52 weeks' treatment with either raloxifene 60 mg/day alone (RLX) or in combination with 17beta-estradiol 1 mg/day (RLX + E) on vasomotor symptoms (n = 83) and endometrial safety (n = 123) in postmenopausal women who transitioned from estrogen-progestin therapy. DESI...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1097/GME.0b013e318031a83d

データ提供：米国国立医学図書館（NLM）

Raloxifene and Estrogen: Navigating the Hormonal Desert

The journey through menopause can be a challenging one, with many women experiencing vasomotor symptoms like hot flashes and night sweats. This study investigates the effects of raloxifene, a selective estrogen receptor modulator (SERM), and estrogen therapy on vasomotor symptoms and endometrial safety in postmenopausal women. The researchers conducted a randomized, double-blind trial where women transitioning from estrogen-progestin therapy received either raloxifene alone or in combination with estrogen. They found that the combination therapy effectively reduced vasomotor symptoms but also led to increased endometrial thickness, raising concerns about potential endometrial stimulation.

Balancing the Hormonal Tides

This study highlights the complexities of hormone replacement therapy in postmenopausal women. While the combination of raloxifene and estrogen effectively reduces vasomotor symptoms, it also poses potential risks to endometrial health. This research underscores the importance of carefully weighing the benefits and risks of hormonal therapies and engaging in open communication with healthcare providers to determine the best course of treatment.

Navigating the Hormonal Desert

The desert of menopause can be a challenging landscape, filled with hormonal fluctuations and unpredictable symptoms. This study provides valuable insights into the potential benefits and risks of hormonal therapies, encouraging us to approach these treatments with a careful and informed perspective.

Dr.Camel's Conclusion

This study highlights the complexities of hormone replacement therapy in postmenopausal women. It emphasizes the importance of carefully weighing the benefits and risks of hormonal therapies and engaging in open communication with healthcare providers to determine the best course of treatment.

Date :
  1. Date Completed 2007-07-12
  2. Date Revised 2015-11-19
Further Info :

Pubmed ID

17314736

DOI: Digital Object Identifier

10.1097/GME.0b013e318031a83d

Related Literature

Article Analysis
・Effects of raloxifene
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.